Last updated on March 2018

Trial of Carfilzomib Lenalidomide Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma


Brief description of study

This is a Phase 3 randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma, eligible to subjects who completed autologous stem cell transplant for symptomatic myeloma who are considered for lenalidomide maintenance.

Detailed Study Description

Primary Objective:

  • To compare progression free survival between Kyprolis (Carfilzomib), Revlimid (lenalidomide), Dexamethasone (KRd) arm and lenalidomide arm

Secondary Objectives

  • To determine the rate of minimal residual negative disease (MRD) at 6 and 12 months after randomization
  • To compare the efficacy (rate of partial response, very good partial response, complete response, and stringent complete response) of KRd vs. Lenalidomide alone after randomization

Clinical Study Identifier: NCT02659293

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.